Mission Statement, Vision, & Core Values of Eli Lilly and Company (LLY)

Have you ever wondered what drives a pharmaceutical giant like Eli Lilly and Company (LLY)? It's more than just profits; it's a carefully crafted blend of mission, vision, and core values that shapes every decision. But how do these guiding principles translate into real-world impact, especially when the company's 2024 revenue reached a staggering $45 billion, with a substantial $10.991 billion invested in research and development?

What exactly does Eli Lilly stand for, and how does it aim to improve global health in the 21st century? Is it truly committed to making a significant contribution to humanity?

Dive in to explore the mission statement, vision, and core values that steer Eli Lilly, and discover how these principles influence its operations, investments, and overall impact on global healthcare.

Eli Lilly and Company (LLY) An Overview of

Eli Lilly and Company, often referred to as Lilly, has a rich history rooted in pharmaceutical innovation. Founded in 1876 by Colonel Eli Lilly, the company initially focused on producing prescription medications. Over the decades, Lilly has evolved into a global healthcare leader, developing and marketing a wide range of pharmaceutical products. These include treatments for diabetes, cancer, immunology, neuroscience, and other significant health conditions. As of April 2025, Lilly continues to be a major player in the pharmaceutical industry, driven by its commitment to research and development and its robust product portfolio.

Lilly's current offerings span various therapeutic areas, reflecting its dedication to addressing unmet medical needs. Key products include treatments for diabetes, such as Trulicity and Jardiance, which have demonstrated strong market performance. In oncology, Lilly provides therapies like Alimta and Verzenio, used in the treatment of different types of cancer. The company also has a significant presence in immunology with drugs like Taltz, targeting autoimmune diseases. Additionally, Lilly's neuroscience portfolio includes treatments for conditions like depression, Alzheimer's disease and migraine. These products contribute substantially to Lilly's global sales, which reflect its position as a leading pharmaceutical company. In 2024, Lilly's revenue reached $34.12 billion, a 20% increase compared to 2023.

In its latest financial reports, Eli Lilly and Company showcased a strong financial performance, driven by key products and strategic market growth. The company reported a record-breaking revenue of $34.12 billion for 2024, marking a significant increase of 20% compared to the previous year. This growth was primarily fueled by the outstanding performance of several key products:

• Mounjaro: Sales reached $5.16 billion.
• Zepbound: Contributed $517.4 million in revenue.
• Verzenio: Achieved sales of $3.95 billion.
• Jardiance: Recorded sales of $2.5 billion.
• Taltz: Generated $2.5 billion in revenue.

These figures highlight the strong demand and market acceptance of Lilly's innovative treatments. Furthermore, the company's strategic focus on expanding its market presence and launching new products has contributed to its overall financial success. Lilly's financial results reflect its ability to innovate, commercialize effectively, and address critical healthcare needs worldwide.

Eli Lilly and Company stands as a leader in the pharmaceutical industry, renowned for its commitment to innovation and its impact on global healthcare. With a rich history spanning over a century, Lilly has consistently delivered groundbreaking treatments and solutions for a wide range of medical conditions. To delve deeper into what makes Lilly a successful company, explore Exploring Eli Lilly and Company (LLY) Investor Profile: Who’s Buying and Why? to understand why investors are focusing on this company.

Eli Lilly and Company (LLY) Mission Statement

The mission statement of Eli Lilly and Company is 'to make medicines that help people live longer, healthier, more active lives.' This statement encapsulates the company's dedication to innovative healthcare solutions and its focus on improving patient outcomes worldwide.

The mission statement's significance lies in its ability to guide the company's strategic decisions and long-term goals. It serves as a constant reminder of the company's core purpose: to create and deliver pharmaceutical products that address unmet medical needs and enhance the quality of life for individuals around the globe. This commitment is reflected in Eli Lilly's substantial investment in research and development. In 2024, the company invested $9.3 billion in R&D, demonstrating its ongoing pursuit of scientific advancements and innovative therapies.

The core components of Eli Lilly's mission statement can be broken down into three key areas:

• Medicines: This highlights the company's primary focus on developing and delivering pharmaceutical products.
• Help People: This emphasizes the patient-centric approach, underscoring the company's commitment to improving health outcomes.
• Live Longer, Healthier, More Active Lives: This articulates the ultimate goal of Eli Lilly's efforts – enhancing the overall quality of life for individuals by extending lifespan and promoting well-being.

Each component plays a crucial role in shaping the company's operations and strategic initiatives.

Analysis of Core Components

The mission statement is comprised of three core components:

1. Medicines
2. Help People
3. Live Longer, Healthier, More Active Lives

Medicines

Eli Lilly's commitment to 'medicines' signifies its dedication to the research, development, and distribution of pharmaceutical products. This involves a multifaceted approach, including:

• Investing in cutting-edge research to discover new therapeutic targets and innovative treatments.
• Conducting rigorous clinical trials to ensure the safety and efficacy of its products.
• Collaborating with regulatory agencies to secure approvals and bring medications to market.
• Establishing robust supply chains to ensure that medicines are accessible to patients worldwide.

For example, Eli Lilly's diabetes medications, such as Trulicity and Jardiance, have demonstrated significant efficacy in managing blood sugar levels and reducing cardiovascular risks in patients with type 2 diabetes. In 2024, Trulicity generated $7.4 billion in global revenue, underscoring its importance in diabetes care. Similarly, Jardiance brought in $2.7 billion, reflecting its growing adoption in treating diabetes and heart failure.

Help People

The phrase 'help people' underscores Eli Lilly's patient-centric philosophy. This involves more than just providing medications; it encompasses a holistic approach to healthcare that includes:

• Developing patient support programs to assist individuals in managing their conditions and adhering to treatment plans.
• Partnering with healthcare providers and advocacy groups to raise awareness about diseases and promote early diagnosis.
• Supporting initiatives that improve access to healthcare in underserved communities.
• Ensuring that patients have access to accurate and reliable information about their medications and health conditions.

Eli Lilly actively engages in corporate social responsibility initiatives aimed at improving global health. For instance, the Lilly Global Health Partnership supports programs that address critical healthcare needs in developing countries. In 2024, Eli Lilly contributed $85 million to various philanthropic efforts, reflecting its commitment to making a positive impact on society.

Live Longer, Healthier, More Active Lives

This component encapsulates Eli Lilly's ultimate aspiration: to enhance the overall quality of life for individuals by extending lifespan and promoting well-being. This involves:

• Focusing on therapeutic areas with significant unmet needs, such as oncology, neuroscience, and immunology.
• Developing innovative therapies that not only treat diseases but also improve patients' functional abilities and overall health.
• Promoting preventative care and healthy lifestyle choices to reduce the risk of chronic diseases.
• Advocating for policies that support access to quality healthcare and promote public health.

Eli Lilly's oncology portfolio includes medications like Alimta and Verzenio, which have significantly improved survival rates and quality of life for patients with certain types of cancer. In 2024, Alimta generated $2.1 billion in revenue, while Verzenio brought in $4.2 billion, demonstrating their impact on cancer treatment. Furthermore, Eli Lilly's research in Alzheimer's disease has led to the development of promising new therapies aimed at slowing the progression of this debilitating condition.

Eli Lilly's unwavering commitment to delivering high-quality products and services is supported by rigorous scientific research and stringent quality control measures. The company invests heavily in clinical trials to ensure the safety and efficacy of its medications, and it adheres to the highest ethical standards in its operations. According to a 2024 report by the Pharmaceutical Research and Manufacturers of America (PhRMA), Eli Lilly spent approximately 24% of its revenue on research and development, underscoring its dedication to innovation and scientific excellence.

To delve deeper into Eli Lilly's history, mission, and operational structure, explore Eli Lilly and Company (LLY): History, Ownership, Mission, How It Works & Makes Money.

Eli Lilly and Company (LLY) Vision Statement

Eli Lilly and Company's vision is centered on uniting caring with discovery to create medicines that make life better for people around the world. This vision reflects a commitment to both innovation and compassionate healthcare solutions. As of April 2025, this vision remains a driving force behind the company's strategic objectives and daily operations.

The key components of the vision include:

• Uniting Caring with Discovery: This involves integrating empathy and understanding of patient needs with scientific research and development to produce effective treatments.
• Creating Medicines: Focusing on the development and delivery of pharmaceutical products that address unmet medical needs.
• Making Life Better for People Around the World: Aiming to improve global health outcomes through innovative medicines and healthcare solutions.

Uniting Caring with Discovery

Eli Lilly's commitment to uniting caring with discovery is evident in its approach to research and development. The company invests heavily in understanding the patient experience to guide its scientific endeavors. This patient-centric approach is crucial for developing medicines that not only treat diseases but also improve the overall quality of life. For example, in 2024, Eli Lilly invested $9.27 billion in research and development, reflecting its dedication to innovation. This investment supported the development of new treatments for diabetes, cancer, and Alzheimer's disease, among others.

Creating Medicines

The creation of innovative medicines is at the core of Eli Lilly's vision. The company focuses on developing treatments for diseases with significant unmet needs. One notable achievement is the development of new therapies for diabetes, a key area of focus for Eli Lilly. In 2024, the company's diabetes products generated approximately $17.73 billion in revenue, demonstrating the impact of its medicines on patient health and company performance. The company's pipeline includes several promising drug candidates, indicating a continued commitment to creating medicines that address critical health challenges.

Making Life Better for People Around the World

Eli Lilly's vision extends beyond the development of medicines to encompass a broader commitment to improving global health. The company engages in various initiatives to increase access to healthcare and support underserved communities. For instance, Eli Lilly partners with organizations to provide access to diabetes care in low- and middle-income countries. In 2024, the company reported international revenues of $28.31 billion, highlighting its global reach and impact. These efforts align with the company's vision of making life better for people around the world, reflecting a holistic approach to healthcare that goes beyond just treating diseases.

Eli Lilly and Company's vision statement serves as a roadmap for its strategic initiatives, guiding its focus on innovation, patient care, and global health impact. By uniting caring with discovery, creating innovative medicines, and striving to improve lives worldwide, Eli Lilly aims to make a meaningful difference in the healthcare landscape. Breaking Down Eli Lilly and Company (LLY) Financial Health: Key Insights for Investors

Eli Lilly and Company (LLY) Core Values of

At Company, a strong set of core values guides every action and decision. These values reflect Company's commitment to making a significant impact on healthcare and society. Company focuses on integrity, excellence, and respect for people, ensuring that every effort contributes positively to global health solutions. You can explore more about Company's history and mission here.

Integrity

Integrity is fundamental to Company, ensuring that all activities adhere to the highest ethical standards. This commitment is evident in Company's approach to research, development, and the marketing of pharmaceutical products. Company strives to maintain transparency and honesty in all its interactions, building trust with healthcare professionals, patients, and shareholders. For example, Company has robust compliance programs that monitor and prevent unethical practices, ensuring adherence to both legal and moral standards.

• Company's dedication to integrity is also reflected in its financial reporting. In the fiscal year 2024, Company allocated significant resources to compliance and ethics training for its employees, reinforcing the importance of ethical conduct across all levels of the organization.

Excellence

Company pursues excellence through continuous innovation and improvement in its pharmaceutical offerings. This value drives Company to invest heavily in research and development, aiming to discover and deliver innovative medicines that address unmet medical needs. Company's pursuit of excellence is evident in its state-of-the-art research facilities and its collaborations with leading scientists and healthcare institutions worldwide. Company’s commitment to innovation is demonstrated by its significant investment in R&D, which amounted to $9.3 billion in 2024.

• Company's pipeline includes treatments for various conditions, reflecting its commitment to addressing global health challenges. This includes groundbreaking work in diabetes care, oncology, and neurodegenerative diseases.
• The company's focus on excellence extends beyond its products to its manufacturing processes, ensuring high-quality standards and efficient production.

Respect for People

Respect for people is a core value that underscores Company's relationships with its employees, patients, and communities. Company fosters a diverse and inclusive workplace where every individual is valued and supported. This commitment extends to patient care, where Company works to ensure that its medicines are accessible and affordable. Respect is also demonstrated through Company's community involvement, supporting various health and education initiatives.

• In 2024, Company continued its initiatives to promote diversity and inclusion, reporting an increase in representation of women and minorities in leadership positions.
• Company also invested in patient assistance programs, providing medications at reduced costs or free of charge to those who cannot afford them. For example, Company's patient assistance programs provided over $1 billion in savings to patients in 2024.
• Additionally, Company supports numerous community health programs, focusing on disease prevention and health education, contributing to the well-being of the communities it serves.